Interleukin – 2 and 6 levels in Nigerian Men with Prostate Cancer
Click to view full paper


prostate cancer

How to Cite

Ofagbor, E. (2022). Interleukin – 2 and 6 levels in Nigerian Men with Prostate Cancer. African Journal of Biomedical Research, 25(1), 13–17. Retrieved from



Prostate cancer is one of the leading causes of cancer mortality in Nigerian males. Multiple cytokines play a role in the aetiopathogenesis of prostate cancer. Interleukin – 2 (IL-2) and – 6 (IL-6) have been identified in the evolution of prostate cancer with possible therapeutic applications. The goal of this study was to investigate the serum levels of these cytokines in Nigerian males with prostate cancer.

Materials and Methods

This was a longitudinal study of 40 serially recruited patients with prostate cancer and 40 age- and sex matched-controls. Blood sample was taken from participants after obtaining informed consent. The samples were processed and analysed for prostate specific antigen (PSA), free PSA, IL-2, and IL-6. 


Plasma levels of IL-2 and IL-6 were significantly elevated in individuals with prostate cancer and directly correlated with plasma PSA and free PSA. The PSA and free PSA levels were also significantly higher in the study group than the control group. The %free PSA was < 25% in all study individuals with malignant prostate cancer and most patients had advanced disease with a Gleason score of 7-9.


The high plasma level of IL-2 in individuals with prostate cancer found in this study suggests active immune response; however, the failure to suppress malignancy may be due to activity modulation in the tumour microenvironment. Observed increase in IL-6 may contribute to disease progression by its direct androgenic action to prostate cancer cells. Hence, the prevalence of advanced disease in this study population may be the result of impaired IL-2 antitumour action and increased IL-6 activity.

Click to view full paper


Adler HL, M. M. (1999). Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. . Journal of urology, 182-187.

Akimoto S, O. A. (1998). Relationship between serum levels of interleukin-6, tumor necrosis factor-α and bone turnover markers in prostate cancer patients. Endocrine journal , 183-189.

Belldegrun A, T. C. (2001). Interleukin 2 Gene Therapy for Prostate Cancer: Phase I Clinical Trial and Basic Biology. Human Gene Therapy, 883-892.

Bray F, F. J. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. . A Cancer Journal for Clinicians, 394-424.

Coussens LM, Z. L. (2013). Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science, 286-291.

Culig Z, P. M. (2018). Interleukin – 6 and prostate cancer, current developments and unsolved questions. . Molecular and Cellular Endocrinology , 25-30.

Culp MB, S. I. (2020). Recent global patterns in prostate cancer incidence and mortality rates. European urology , 38-52.

Drachenberg DE, E. A. (1999 ). Circulating levels of interleukin‐6 in patients with hormone refractory prostate cancer. . The Prostate, 127-133.

Dunn GP, B. A. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. . Nature immunology, 991-998.

Ekeke ON, A. O. (2012). Management of Prostate Cancer in Port Harcourt, Nigeria: Changing Patterns. Journal of the West African College of Surgeons, 58-77.

Ekeke ON, A. O. (2012). Management of Prostate Cancer in Port Harcourt, Nigeria: Changing Patterns. J West Afr Coll Surg 2012; 2(3):58-77, 58-77.

Ekeke ON, A. O. (2012). Management of Prostate Cancer in Port Harcourt, Nigeria: Changing Patterns. . J West Afr Coll Surg, 58-77.

Emiogun EF, W. O. (2019). Epidemiology of prostate cancer in Nigeria: Observations at Lagos State University Teaching Hospital. . Cancer Health Disparities.

Giri D, O. M. (2001). Interleukin-6 is an autocrine growth factor in human prostate cancer. . The American journal of pathology, 2159-2165.

Hanahan D, W. R. (2000). The hallmarks of cancer. Cell, 57-70.

Ikuerowo SO, O. O. (2013). Prevalence and characteristics of prostate cancer among participants of a community- based screening in Nigeria using serum prostate specific antigen and digital rectal examination. Pan African Medical Journal, 129.

Kourtzelis I, R. S. (2016). The dual role of complement in cancer and its implication in anti-tumor therapy. Ann Transl Med , 265.


Mechergui YB, J. A. (2009). The profile of prostate epithelial cytokines and its impact on sera prostate specific antigen levels. Inflammation, 202-210.

Natarajan K, D. N. (2002). Structure and function of natural- killer-cell receptors: multiple molecular solutions to self, non- self-discrimination. Annu. Rev. Immunol , 853.

Nguyen DP, L. J. (2014). Inflammation and prostate cancer: the role of interleukin 6 (IL‐6). . BJU international 2014 Jun;113(6):986-992., 986-992.

Okamoto M, L. C. (1997). Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer research, 141-146.

Quatan N, M. B. (2006). Persistently high levels of immunosuppressive cytokines in patients after radical prostatectomy. Prostate Cancer and Prostatic Diseases, 420-425.

Rutkowski MJ, S. M. (2010). Cancer and the complement cascade. . Mol Cancer Res, 53-65.

Sfanos KS, D. A. (2012). Prostate cancer and inflammation: the evidence. Histopathology , 199-215.

Shariat SF, A. B. (2001). Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology , 1008-1015.

Silvestri I, T. E. (2019). Immunotherapy in prostate cancer: recent advances and future directions. . UROLOGY.

Tazaki E, S. N. (2011). Serum cytokine profiles in patients with prostate carcinoma. . Experimental and therapeutic medicine 2011 Sep 1;2(5):887-891., 887-891.

Ugochukwu UV, O. O. (2019). Prostate cancer screening: what do men know, think and do about their risk? exploring the opinions of men in an urban area in Lagos State, Nigeria: a mixed methods survey. The Pan African Medical Journal, 34.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2022 African Journal of Biomedical Research